Chromogranin A (CGA) is a member of the granin family of proteins which are widespread in endocrine, neuroendocrine, peripheral, and central nervous tissues, where they are typically found in secretory granules. It is well accepted that CGA cooperates to regulate synthesis and secretion of these various granule signaling molecules.Because of its ubiquitous distribution within neuroendocrine tissues, CGA can be a useful diagnostic marker for neuroendocrine neoplasms, including carcinoids, pheochromocytomas, neuroblastomas, medullary thyroid carcinomas (MTC), some pituitary tumors, functioning and nonfunctioning islet cell tumors and other amine precursor uptake and decarboxylation (APUD) tumors. It is also useful as a prognostic marker for detection of recurrence and monitoring of response to different treatments. As other tumor markers, it is imperative to know its physiology and pathophysiology, its sensitivity and specificity in different neuroendocrine tumors (NETs), and carefully integrate these data with the clinical data of the single patient, to maximize its diagnostic/prognostic index.

Bottoni, P., De Michele, T., Scatena, R., A Critical Approach to Clinical Biochemistry of Chromogranin A, in Scatena, R. (ed.), Advances in Cancer Biomarkers, Springer, Dordrecht 2015: <<ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY>>, 867 317- 323. 10.1007/978-94-017-7215-0_19 [http://hdl.handle.net/10807/70088]

A Critical Approach to Clinical Biochemistry of Chromogranin A

Bottoni, Patrizia;De Michele, Teresa;Scatena, Roberto
2015

Abstract

Chromogranin A (CGA) is a member of the granin family of proteins which are widespread in endocrine, neuroendocrine, peripheral, and central nervous tissues, where they are typically found in secretory granules. It is well accepted that CGA cooperates to regulate synthesis and secretion of these various granule signaling molecules.Because of its ubiquitous distribution within neuroendocrine tissues, CGA can be a useful diagnostic marker for neuroendocrine neoplasms, including carcinoids, pheochromocytomas, neuroblastomas, medullary thyroid carcinomas (MTC), some pituitary tumors, functioning and nonfunctioning islet cell tumors and other amine precursor uptake and decarboxylation (APUD) tumors. It is also useful as a prognostic marker for detection of recurrence and monitoring of response to different treatments. As other tumor markers, it is imperative to know its physiology and pathophysiology, its sensitivity and specificity in different neuroendocrine tumors (NETs), and carefully integrate these data with the clinical data of the single patient, to maximize its diagnostic/prognostic index.
Inglese
Advances in Cancer Biomarkers
978-94-017-7214-3
867
Bottoni, P., De Michele, T., Scatena, R., A Critical Approach to Clinical Biochemistry of Chromogranin A, in Scatena, R. (ed.), Advances in Cancer Biomarkers, Springer, Dordrecht 2015: <<ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY>>, 867 317- 323. 10.1007/978-94-017-7215-0_19 [http://hdl.handle.net/10807/70088]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/70088
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact